Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656737 | 0.89 | CYP19A1 (0.33) | CYP19A1KMT2AMEN1CYP26A1 | |
| SCHEMBL11202221 | 0.80 | HSP90AA1 (0.38) | CYP19A1KMT2AMEN1HSP90AA1CYP3A4 | |
| SCHEMBL6999923 | 0.80 | CYP19A1 (0.38) | CYP19A1KMT2AMEN1HSP90AA1CYP3A4 | |
| SCHEMBL8453886 | 0.71 | — | — | |
| SCHEMBL5306513 | 0.71 | FAAH (0.49) | CYP19A1KMT2AMEN1HSP90AA1CYP3A4 | |
| SCHEMBL502219 | 0.70 | CYP1A2 (0.43) | CYP19A1KMT2AMEN1HSP90AA1CYP3A4 | |
| SCHEMBL10361017 | 0.70 | ALDH1A1 (0.46) | CYP19A1KMT2AMEN1HSP90AA1CYP3A4 | |
| SCHEMBL20981285 | 0.70 | CYP19A1 (0.38) | CYP19A1KMT2AMEN1HSP90AA1CYP3A4 | |
| SCHEMBL15688936 | 0.70 | CYP19A1 (0.38) | CYP19A1KMT2AMEN1HSP90AA1CYP3A4 | |
| SCHEMBL6470267 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | CYP19A1 193/4885KMT2A 3395/4885MEN1 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.